Advertisement

Analysis of neurotransmitter levels in addiction-related brain regions during synthetic cathinone self-administration in male Sprague-Dawley rats

  • Julie A. MarusichEmail author
  • Elaine A. Gay
  • Bruce E. Blough
Original Investigation

Abstract

Rationale

Synthetic cathinones are used as stimulants of abuse. Different stimulants may induce distinct rates of disease progression, yielding neurochemical changes that may vary across brain regions or neurotransmitter systems.

Objectives

This research sought to behaviorally and chemically differentiate stages of synthetic cathinone abuse through rodent self-administration and measurement of the neurotransmitter profile in multiple brain regions.

Methods

Male rats were trained to self-administer α-PVP, mephedrone (4MMC), or saline. Half of each drug group stopped self-administering after autoshaping; the other half self-administered for another 21 days. Brain tissue from amygdala, hippocampus, hypothalamus, PFC, striatum, and thalamus was profiled with electrochemical detection to assess neurotransmitter levels.

Results

During autoshaping, the majority of infusions were delivered noncontingently. In the self-administration phase, rats responded more for α-PVP and 4MMC than for saline, demonstrating that both synthetic cathinones were reinforcing. Longer durations of exposure elevated 5-HIAA in hypothalamus, PFC, and hippocampus, indicating that learning may produce changes in addiction-related brain regions. Both synthetic cathinones decreased norepinephrine in hippocampus, while α-PVP decreased glutamate in hippocampus and PFC, and 4MMC decreased glutamate in thalamus. Furthermore, α-PVP increased dopaminergic metabolites in striatum, whereas 4MMC decreased serotonin in the amygdala, hippocampus, and PFC. Interestingly, neither synthetic cathinone affected dopamine levels despite their functional effects on the dopaminergic system.

Conclusions

In summary, the neurotransmitter changes observed here suggest that synthetic cathinone use likely produces sequential neurochemical changes during the transition from use to abuse. Consequently, treatment need may differ depending on the progression of synthetic cathinone abuse.

Keywords

α-PVP Mephedrone Neurotransmitter Self-administration 

Notes

Acknowledgements

The authors have no conflicts of interest. The authors thank Daniel Barrus, Ricardo Cortes, Tony Landavazo, Timothy Lefever, Nikita Pulley, Shanequa Taylor, Scott Watson, and Jenny Wiley for technical assistance. Research was generously supported by National Institute of Health grants DA039315 and DA012970. The funding source had no other role other than financial support.

References

  1. Aarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA (2015) In vivo potency and efficacy of the novel cathinone alpha-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology 232:3045–3055.  https://doi.org/10.1007/s00213-015-3944-8 CrossRefGoogle Scholar
  2. Baumann MH (2014) Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addiction 109:1577–1579.  https://doi.org/10.1111/add.12601 CrossRefGoogle Scholar
  3. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF et al (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203.  https://doi.org/10.1038/npp.2011.304 CrossRefGoogle Scholar
  4. Baumann MH, Bukhari MO, Lehner KR, Anizan S, Rice KC, Concheiro M, Huestis MA (2017) Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Curr Top Behav Neurosci 32:93–117.  https://doi.org/10.1007/7854_2016_53 CrossRefGoogle Scholar
  5. Baumann MH, Partilla JS, Lehner KR (2013) Psychoactive “bath salts”: not so soothing. Eur J Pharmacol 698:1–5.  https://doi.org/10.1016/j.ejphar.2012.11.020 CrossRefGoogle Scholar
  6. Baumann MH, Solis E Jr, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL (2014) Bath salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34:15150–15158.  https://doi.org/10.1523/JNEUROSCI.3223-14.2014 CrossRefGoogle Scholar
  7. Brennan KA, Colussi-Mas J, Carati C, Lea RA, Fitzmaurice PS, Schenk S (2010) Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat. Brain Res 1317:137–146.  https://doi.org/10.1016/j.brainres.2009.11.069 CrossRefGoogle Scholar
  8. Bu Q, Lv L, Yan G, Deng P, Wang Y, Zhou J, Yang Y, Li Y, Cen X (2013) NMR-based metabonomic in hippocampus, nucleus accumbens and prefrontal cortex of methamphetamine-sensitized rats. Neurotoxicology 36:17–23.  https://doi.org/10.1016/j.neuro.2013.02.007 CrossRefGoogle Scholar
  9. Burrell MH, Atcherley CW, Heien ML, Lipski J (2015) A novel electrochemical approach for prolonged measurement of absolute levels of extracellular dopamine in brain slices. ACS Chem Neurosci 6:1802–1812.  https://doi.org/10.1021/acschemneuro.5b00120 CrossRefGoogle Scholar
  10. Cameron K, Kolanos R, Vekariya R, De Felice L, Glennon RA (2013) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of “bath salts,” produce opposite effects at the human dopamine transporter. Psychopharmacology 227:493–499.  https://doi.org/10.1007/s00213-013-2967-2 CrossRefGoogle Scholar
  11. Carroll ME, Lac ST (1993) Autoshaping i.v. cocaine self-administration in rats: effects of nondrug alternative reinforcers on acquisition. Psychopharmacology 110:5–12CrossRefGoogle Scholar
  12. Chiu K, Lau WM, Lau HT, So KF, Chang RC (2007) Micro-dissection of rat brain for RNA or protein extraction from specific brain region. J Vis Exp 269.  https://doi.org/10.3791/269
  13. Creehan KM, Vandewater SA, Taffe MA (2015) Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90–97.  https://doi.org/10.1016/j.neuropharm.2015.01.003 CrossRefGoogle Scholar
  14. Darvesh AS, Carroll RT, Geldenhuys WJ, Gudelsky GA, Klein J, Meshul CK, Van der Schyf CJ (2011) In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery. Expert Opin Drug Discovery 6:109–127.  https://doi.org/10.1517/17460441.2011.547189 CrossRefGoogle Scholar
  15. Derungs A, Schietzel S, Meyer MR, Maurer HH, Krahenbuhl S, Liechti ME (2011) Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol (Phila) 49:691–693.  https://doi.org/10.3109/15563650.2011.592838 CrossRefGoogle Scholar
  16. Fratantonio J, Andrade L, Febo M (2015) Designer drugs: a synthetic catastrophe. J Reward Defic Syndr 1:82–86.  https://doi.org/10.17756/jrds.2015-014 CrossRefGoogle Scholar
  17. Gannon BM, Galindo KI, Mesmin MP, Sulima A, Rice KC, Collins GT (2018) Relative reinforcing effects of second-generation synthetic cathinones: acquisition of self-administration and fixed ratio dose-response curves in rats. Neuropharmacology 134:28–35.  https://doi.org/10.1016/j.neuropharm.2017.08.018 CrossRefGoogle Scholar
  18. Gannon BM, Rice KC, Collins GT (2017) Reinforcing effects of abused ‘bath salts’ constituents 3,4-methylenedioxypyrovalerone and alpha-pyrrolidinopentiophenone and their enantiomers. Behav Pharmacol 28:578–581.  https://doi.org/10.1097/FBP.0000000000000315 CrossRefGoogle Scholar
  19. Garris PA, Christensen JR, Rebec GV, Wightman RM (1997) Real-time measurement of electrically evoked extracellular dopamine in the striatum of freely moving rats. J Neurochem 68:152–161CrossRefGoogle Scholar
  20. German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2–8.  https://doi.org/10.1016/j.lfs.2013.07.023 CrossRefGoogle Scholar
  21. Ghanbari R, Sumner S (2018) Using metabolomics to investigate biomarkers of drug addiction. Trends Mol Med 24:197–205.  https://doi.org/10.1016/j.molmed.2017.12.005 CrossRefGoogle Scholar
  22. Glennon RA, Young R (2016) Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinovalerophenone (alpha-PVP). Brain Res Bull 126:111–126.  https://doi.org/10.1016/j.brainresbull.2016.04.011 CrossRefGoogle Scholar
  23. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530–536.  https://doi.org/10.1124/jpet.111.184119 CrossRefGoogle Scholar
  24. Honkanen A (1999) Modulation of brain dopaminergic neurotransmission in alcohol-preferring rats by alcohol and opioids. Dissertation, University of HelsinkiGoogle Scholar
  25. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48:653–683.  https://doi.org/10.1146/annurev.pharmtox.48.113006.094715 CrossRefGoogle Scholar
  26. Kaplan KA, Chiu VM, Lukus PA, Zhang X, Siems WF, Schenk JO, Hill HH Jr (2013) Neuronal metabolomics by ion mobility mass spectrometry: cocaine effects on glucose and selected biogenic amine metabolites in the frontal cortex, striatum, and thalamus of the rat. Anal Bioanal Chem 405:1959–1968.  https://doi.org/10.1007/s00216-012-6638-7 CrossRefGoogle Scholar
  27. Karila L, Megarbane B, Cottencin O, Lejoyeux M (2015) Synthetic cathinones: a new public health problem. Curr Neuropharmacol 13:12–20.  https://doi.org/10.2174/1570159X13666141210224137 CrossRefGoogle Scholar
  28. Katz DP, Bhattacharya D, Bhattacharya S, Deruiter J, Clark CR, Suppiramaniam V, Dhanasekaran M (2014) Synthetic cathinones: “a khat and mouse game”. Toxicol Lett 229:349–356.  https://doi.org/10.1016/j.toxlet.2014.06.020 CrossRefGoogle Scholar
  29. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949–1958.  https://doi.org/10.1111/j.1476-5381.2011.01499.x CrossRefGoogle Scholar
  30. Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci 8:1442–1444.  https://doi.org/10.1038/nn1105-1442 CrossRefGoogle Scholar
  31. Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Annu Rev Psychol 59:29–53.  https://doi.org/10.1146/annurev.psych.59.103006.093548 CrossRefGoogle Scholar
  32. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238.  https://doi.org/10.1038/npp.2009.110 CrossRefGoogle Scholar
  33. Lacan G, Hadamitzky M, Kuczenski R, Melega WP (2013) Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration. Synapse 67:476–488.  https://doi.org/10.1002/syn.21654 CrossRefGoogle Scholar
  34. Lecca D, Cacciapaglia F, Valentini V, Acquas E, Di Chiara G (2007) Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. Psychopharmacology 191:653–667.  https://doi.org/10.1007/s00213-006-0496-y CrossRefGoogle Scholar
  35. Li Y, Yan GY, Zhou JQ, Bu Q, Deng PC, Yang YZ, Lv L, Deng Y, Zhao JX, Shao X, Zhu RM, Huang YN, Zhao YL, Cen XB (2012) (1)H NMR-based metabonomics in brain nucleus accumbens and striatum following repeated cocaine treatment in rats. Neuroscience 218:196–205.  https://doi.org/10.1016/j.neuroscience.2012.05.019 CrossRefGoogle Scholar
  36. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213.  https://doi.org/10.1016/j.neuropharm.2014.02.016 CrossRefGoogle Scholar
  37. Marusich JA, Beckmann JS, Gipson CD, Bardo MT (2010) Methylphenidate as a reinforcer for rats: contingent delivery and intake escalation. Exp Clin Psychopharmacol 18:257–266.  https://doi.org/10.1037/a0019814 CrossRefGoogle Scholar
  38. Marusich JA, Beckmann JS, Gipson CD, Bardo MT (2011) Cue effects on methylphenidate self-administration in rats. Behav Pharmacol 22:714–717.  https://doi.org/10.1097/FBP.0b013e32834afed1 CrossRefGoogle Scholar
  39. Marusich JA, Grant KR, Blough BE, Wiley JL (2012) Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 33:1305–1313.  https://doi.org/10.1016/j.neuro.2012.08.003 CrossRefGoogle Scholar
  40. Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL (2016) Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology 55:83–91.  https://doi.org/10.1016/j.neuro.2016.05.015 CrossRefGoogle Scholar
  41. Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM, Wyatt N, Callaghan PD, Bowen MT, Cornish JL, McGregor IS (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 27:823–836.  https://doi.org/10.1177/0269881113490325 CrossRefGoogle Scholar
  42. Motbey CP, Karanges E, Li KM, Wilkinson S, Winstock AR, Ramsay J, Hicks C, Kendig MD, Wyatt N, Callaghan PD, McGregor IS (2012) Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 7:e45473.  https://doi.org/10.1371/journal.pone.0045473 CrossRefGoogle Scholar
  43. National Research Council (2011) Guide for the care and use of laboratory animals, 8th edn. National Academies Press (US), Washington, D.C.Google Scholar
  44. NDEWS (2015) National Drug Early Warning System (NDEWS) sentinel community site profile 2015: southeastern Florida. National Drug Early Warning SystemGoogle Scholar
  45. NDEWS (2016a) Maine sentinel community site drug use patterns and trends, 2016. National Drug Early Warning SystemGoogle Scholar
  46. NDEWS (2016b) Southeastern Florida (Miami area) sentinel community site drug use patterns and trends, 2016. National Drug Early Warning SystemGoogle Scholar
  47. NDEWS (2017) Sentinel community site cross-site data presentation: National Forensic Laboratory Information System (NFLIS) 2016 vol cross-site data presentation: NFLIS-19. National Drug Early Warning System Coordinating CenterGoogle Scholar
  48. Nesbitt KM, Jaquins-Gerstl A, Skoda EM, Wipf P, Michael AC (2013) Pharmacological mitigation of tissue damage during brain microdialysis. Anal Chem 85:8173–8179.  https://doi.org/10.1021/ac401201x CrossRefGoogle Scholar
  49. Nguyen JD, Bremer PT, Ducime A, Creehan KM, Kisby BR, Taffe MA, Janda KD (2017a) Active vaccination attenuates the psychostimulant effects of alpha-PVP and MDPV in rats. Neuropharmacology 116:1–8.  https://doi.org/10.1016/j.neuropharm.2016.12.005 CrossRefGoogle Scholar
  50. Nguyen JD, Grant Y, Creehan KM, Vandewater SA, Taffe MA (2017b) Escalation of intravenous self-administration of methylone and mephedrone under extended access conditions. Addict Biol 22:1160–1168.  https://doi.org/10.1111/adb.12398 CrossRefGoogle Scholar
  51. Orejarena MJ, Berrendero F, Maldonado R, Robledo P (2009) Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice. Psychopharmacology 205:457–466.  https://doi.org/10.1007/s00213-009-1554-z CrossRefGoogle Scholar
  52. Patkar AA, Rozen S, Mannelli P, Matson W, Pae CU, Krishnan KR, Kaddurah-Daouk R (2009) Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. Psychopharmacology 206:479–489.  https://doi.org/10.1007/s00213-009-1625-1 CrossRefGoogle Scholar
  53. Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42.  https://doi.org/10.1007/s13181-011-0193-z CrossRefGoogle Scholar
  54. Reinhoud NJ, Brouwer HJ, van Heerwaarden LM, Korte-Bouws GA (2013) Analysis of glutamate, GABA, noradrenaline, dopamine, serotonin, and metabolites using microbore UHPLC with electrochemical detection. ACS Chem Neurosci 4:888–894.  https://doi.org/10.1021/cn400044s CrossRefGoogle Scholar
  55. Rodeberg NT, Sandberg SG, Johnson JA, Phillips PE, Wightman RM (2017) Hitchhiker’s guide to voltammetry: acute and chronic electrodes for in vivo fast-scan cyclic voltammetry. ACS Chem Neurosci 8:221–234.  https://doi.org/10.1021/acschemneuro.6b00393 CrossRefGoogle Scholar
  56. Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, Sandtner W, Ecker GF, Sitte HH, Baumann MH (2015) ‘Second-generation’ mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40:1321–1331.  https://doi.org/10.1038/npp.2014.325 CrossRefGoogle Scholar
  57. Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, Pillidge KE et al (2013) Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol 23:1085–1095.  https://doi.org/10.1016/j.euroneuro.2012.09.005 CrossRefGoogle Scholar
  58. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470.  https://doi.org/10.1111/j.1476-5381.2012.02145.x CrossRefGoogle Scholar
  59. Spijker S (2011) Dissection of rodent brain regions. In: Li KW (ed) Neuroproteomics. Humana Press, Totowa, NJ, pp 13–26.  https://doi.org/10.1007/978-1-61779-111-6_2 CrossRefGoogle Scholar
  60. Striebel JM, Pierre JM (2011) Acute psychotic sequelae of “bath salts”. Schizophr Res 133:259–260.  https://doi.org/10.1016/j.schres.2011.09.001 CrossRefGoogle Scholar
  61. U.S. Department of Justice DEA (2017) 2017 National Drug Threat Assessment. Springfield, VAGoogle Scholar
  62. Vandewater SA, Creehan KM, Taffe MA (2015) Intravenous self-administration of entactogen-class stimulants in male rats. Neuropharmacology 99:538–545.  https://doi.org/10.1016/j.neuropharm.2015.08.030 CrossRefGoogle Scholar
  63. Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C (2012) Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 8:65–68.  https://doi.org/10.1007/s13181-011-0199-6 CrossRefGoogle Scholar
  64. Wood DM, Greene SL, Dargan PI (2011) Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 28:280–282.  https://doi.org/10.1136/emj.2010.092288 CrossRefGoogle Scholar
  65. Zaitsu K, Miyawaki I, Bando K, Horie H, Shima N, Katagi M, Tatsuno M, Bamba T, Sato T, Ishii A, Tsuchihashi H, Suzuki K, Fukusaki E (2014) Metabolic profiling of urine and blood plasma in rat models of drug addiction on the basis of morphine, methamphetamine, and cocaine-induced conditioned place preference. Anal Bioanal Chem 406:1339–1354.  https://doi.org/10.1007/s00216-013-7234-1 CrossRefGoogle Scholar
  66. Zhang X, Chiu VM, Todd RP, Sorg BA, Hill HH Jr (2016) Neuronal metabolomics by ion mobility mass spectrometry in cocaine self-administering rats after early and late withdrawal. Anal Bioanal Chem 408:4233–4245.  https://doi.org/10.1007/s00216-016-9508-x CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Drug DiscoveryRTI InternationalResearch Triangle ParkUSA

Personalised recommendations